Literature DB >> 999542

Hartnup disease. Clinical, pathological, and biochemical observations.

A J Tahmoush, D H Alpers, R D Feigin, V Armbrustmacher, A L Prensky.   

Abstract

Hartnup disease is a rare genetic disorder of amino acid transport associated with variable and intermittent clinical abnormalities. A family is described in which three siblings had an intermittently progressive neurological disease and two of the affected siblings had the Hartnup-pattern aminoaciduria. Neuropathological examination of one case showed severe diffuse atrophy, generalized neuronal loss in the cortex, and Purkinje cell loss in the cerebellum. In vivo and in vitro studies of intestinal amino acid transport in the surviving sibling indicated a partial defect in the transport of several neutral amino acids (tryptophan, alanine, serine, and methionine) with normal transport of other neutral amino acids (threonine, phenylalanine, histidine, tyrosine, and isoleucine). Transport of glycine, proline, hydroxyproline, and the basic amino acids appeared normal.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 999542     DOI: 10.1001/archneur.1976.00500120001001

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  4 in total

1.  Hartnup syndrome, progressive encephalopathy and allo-albuminaemia. A clinico-pathological case study.

Authors:  K Schmidtke; W Endres; A Roscher; H Ibel; N Herschkowitz; C Bachmann; E Plöchl; H B Hadorn
Journal:  Eur J Pediatr       Date:  1992-12       Impact factor: 3.183

Review 2.  The genetics of primary torsion dystonia.

Authors:  U Müller; K G Kupke
Journal:  Hum Genet       Date:  1990-01       Impact factor: 4.132

3.  Circumvention of defective neutral amino acid transport in Hartnup disease using tryptophan ethyl ester.

Authors:  A J Jonas; I J Butler
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

Review 4.  NAD+ homeostasis in human health and disease.

Authors:  Rubén Zapata-Pérez; Ronald J A Wanders; Clara D M van Karnebeek; Riekelt H Houtkooper
Journal:  EMBO Mol Med       Date:  2021-05-27       Impact factor: 12.137

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.